BR112022025334A2 - Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo - Google Patents

Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo

Info

Publication number
BR112022025334A2
BR112022025334A2 BR112022025334A BR112022025334A BR112022025334A2 BR 112022025334 A2 BR112022025334 A2 BR 112022025334A2 BR 112022025334 A BR112022025334 A BR 112022025334A BR 112022025334 A BR112022025334 A BR 112022025334A BR 112022025334 A2 BR112022025334 A2 BR 112022025334A2
Authority
BR
Brazil
Prior art keywords
present
fusion protein
same
protein
insulin
Prior art date
Application number
BR112022025334A
Other languages
English (en)
Inventor
Yu Ge
Chen Wei
Luo Li
Original Assignee
Ningbo Kunpeng Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Kunpeng Biotech Co Ltd filed Critical Ningbo Kunpeng Biotech Co Ltd
Publication of BR112022025334A2 publication Critical patent/BR112022025334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22044—Nuclear-inclusion-a endopeptidase (3.4.22.44)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

DERIVADO DE INSULINA DEGLUDECA, MÉTODO DE PREPARAÇÃO PARA O MESMO, E APLICAÇÃO DO MESMO. A presente invenção fornece um derivado de insulina degludeca e um método de preparação do mesmo. Especificamente, a presente invenção fornece uma proteína de fusão compreendendo uma unidade de dobra de proteína fluorescente verde e um precursor de insulina degludeca ou um fragmento ativo do mesmo. A proteína de fusão da presente invenção tem um nível de expressão significativamente aumentado e a proteína precursora de insulina degludeca na proteína de fusão é dobrada corretamente e tem atividade biológica. Além disso, a unidade de dobra de proteína fluorescente verde na proteína de fusão da presente invenção pode ser digerida em pequenos fragmentos por uma protease, que têm uma grande diferença no peso molecular em comparação com uma proteína alvo e são fáceis de separar. A presente invenção fornece adicionalmente um método para usar a proteína de fusão para preparar insulina degludeca e preparar um intermediário da mesma.
BR112022025334A 2020-06-10 2021-06-10 Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo BR112022025334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010524886.5A CN113773398B (zh) 2020-06-10 2020-06-10 一种德谷胰岛素衍生物及其应用
PCT/CN2021/099493 WO2021249505A1 (zh) 2020-06-10 2021-06-10 一种德谷胰岛素衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112022025334A2 true BR112022025334A2 (pt) 2023-03-07

Family

ID=78834815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025334A BR112022025334A2 (pt) 2020-06-10 2021-06-10 Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo

Country Status (6)

Country Link
US (1) US20230127875A1 (pt)
EP (1) EP4166573A1 (pt)
JP (1) JP2023531168A (pt)
CN (2) CN113773398B (pt)
BR (1) BR112022025334A2 (pt)
WO (1) WO2021249505A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116425884B (zh) * 2023-03-09 2024-04-26 北京惠之衡生物科技有限公司 一种德谷胰岛素的纯化及制备方法
CN117782730A (zh) * 2023-12-27 2024-03-29 亿帆医药(上海)有限公司 德谷胰岛素中大肠杆菌菌体蛋白残留的检测试剂和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
AU2012350586B2 (en) * 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
CN102628072B (zh) * 2012-03-20 2013-12-04 甘李药业股份有限公司 一种胰岛素的制备方法
US9714274B2 (en) * 2012-03-23 2017-07-25 Suzhou Kunpeng Biotech Co., Ltd. Fusion proteins of superfolder green fluorescent protein and use thereof
CN105820233B (zh) * 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN109295067B (zh) * 2018-10-26 2020-12-29 吉林惠升生物制药有限公司 一种密码子优化的德谷胰岛素前体基因及其表达方法
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途

Also Published As

Publication number Publication date
EP4166573A1 (en) 2023-04-19
CN113773398A (zh) 2021-12-10
WO2021249505A1 (zh) 2021-12-16
JP2023531168A (ja) 2023-07-21
CN113773398B (zh) 2023-05-23
US20230127875A1 (en) 2023-04-27
CN115708413A (zh) 2023-02-21

Similar Documents

Publication Publication Date Title
BR112022025334A2 (pt) Derivado de insulina degludeca, método de preparação do mesmo, e uso do mesmo
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
Li et al. NaKtide, a Na/K-ATPase-derived peptide Src inhibitor, antagonizes ouabain-activated signal transduction in cultured cells
Santhoshkumar et al. Significance of interactions of low molecular weight crystallin fragments in lens aging and cataract formation
Xu et al. Curcumin induces the apoptosis of non-small cell lung cancer cells through a calcium signaling pathway
BR112012032708A2 (pt) proteína de fusão anticâncer.
Lei et al. Effect of sonication on thermolysin hydrolysis of ovotransferrin
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112014015339A8 (pt) compostos para inibição da interação de bcl2 com parceiros de ligação
Lo et al. Identification of the bioactive and consensus peptide motif from Momordica charantia insulin receptor-binding protein
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
BRPI0715818B8 (pt) método para produzir uma biblioteca compreendendo derivados recombinantes do domínio de homologia src 3 (sh3) da quinase fyn
BR112012012025A2 (pt) polipeptídeo imunomodulador derivado da interleucina-2, proteína de fusão, composição farmacêutica e usos do polipeptídeo e da proteína de fusão
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
BR112013000255A2 (pt) ácidos hidróxifenil-hexinoicos substituídos por ariloxialquileno, método para preparação dos mesmos e seu uso dos mesmos como um medicamento
BRPI0820749B8 (pt) derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos
BR112022025335A2 (pt) Derivado de semaglutida, e método de preparação para o mesmo e aplicação do mesmo
BR112013010844A2 (pt) nova endolisina
BR112014015274A2 (pt) compostos e composições para inibição da interação de bcl2 com parceiros de ligação
BR112012000115B8 (pt) composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
BR112017011552A2 (pt) derivados de fgf21 e seu uso